I would expect the share price to double or more almost immediately. Leronlimab is in final stages of phase 2 and 3 trials and has already established a good safety record. Reaching statistical significance (with a more appropriate one-sided test, their p-value would be 0.043...with the much larger sample size and the same effect size, leronlimab would show those beautiful results that would shock the world) in the primary outcome would mean removal of a huge doubts, bring lots of attention, lots of investor interest, and lots of future income.

I know very little about investing, though, so my wild guess of "double or more" is really just a wild guess.